Sosimerasib Cas 2839563-01-6 MF C36H39ClFN7O4 MW688.2 g/mol (2R,4aR,8M)-11-chloro-6-[2-(dimethylamino)ethyl]-10-(2-fluoro-6-hydroxyphenyl)-2-methyl-8-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-3-(prop-2-enoyl)-2,3,4,4a,6,8-hexahydro-1Hpyrazino[1′,2′:4,5]pyrazino[2,3-c][1,8]naphthyridine-5,7-dione (4R,7R)-16-chloro-9-[2-(dimethylamino)ethyl]-15-(2-fluoro-6-hydroxyphenyl)-4-methyl-12-(4-methyl-2-propan-2-yl-3-pyridinyl)-5-prop-2-enoyl-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione 1H-Pyrazino[1′,2′:4,5]pyrazino[2,3-c][1,8]naphthyridine-5,7-dione, 11-chloro-6-[2-(dimethylamino)ethyl]-10-(2-fluoro-6-hydroxyphenyl)-2,3,4,4a,6,8-hexahydro-2-methyl-8-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-3-(1-oxo-2-propen-1-yl)-, (2R,4aR,8R)- (4R,7R)-16-chloro-9-[2-(dimethylamino)ethyl]-15-(2-fluoro-6-hydroxyphenyl)-4-methyl-12-(4-methyl-2-propan-2-yl-3-pyridinyl)-5-prop-2-enoyl-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione (2R,4aR,8M)-11-chloro-6-[2-(dimethylamino)ethyl]-10-(2-fluoro-6-hydroxyphenyl)-2-methyl-8-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-3-(prop-2-enoyl)-2,3,4,4a,6,8-hexahydro-1Hpyrazino[1′,2′:4,5]pyrazino[2,3-c][1,8]naphthyridine-5,7-dioneKirsten rat sarcoma viral oncogene homolog inhibitor, antineoplastic, HBI-2438, JMKX1899, HBI 2438,…
Tiratricol CAS 51-24-1, 1477-04-9 (hydrochloride salt) MFC14H9I3O4 MW621.93 g/mol 9/28/2026, Emcitate, FDA 2026, APPROVALS 2026, Triac 2-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid 3,3′,5-TRIIODOTHYROACETIC ACID Triiodothyroacetic acid To treat peripheral…
Zilurgisertib CAS 2173389-57-4 MW 502.6 g/mol MFC30H38N4O3 Atebrioz, FDA 2026, APPROVALS 2026, L5Z9S25HO2, INCB 000928 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[(1R,5S)-3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide To reduce the volume of total new heterotopic ossification…
Tavapadon CAS No.:1643489-24-0 Formula:C19H16F3N3O3 Molecular Weight:391.34 9/25/2026, Juvmo, FDA 2026, APPROVALS 2026, CEREVEL, CVL 751, PF 6649751, PF-06649751, To treat Parkinson’s disease in adults Tavapadon…
“Patents are good for 20 years after the invention…”
Not quite correct, a US patent term is now in line with the practice in most countries. It’s a 20 year term from the grant. Also for pharmaceuticals, there are possible patent term extensions of up to 5 years under Hatch-Waxman. It should also be noted that FDA can grant patent-like exclusivity, which varies depending on the circumstance.
LikeLike
Reblogged this on MEDCHEMEGYPT.
LikeLike
Reblogged this on MedCheminAustralia.
LikeLike
Reblogged this on MariaGairos–DRUGS.
LikeLike
Reblogged this on MedCheminSingapore by Sushma Wang.
LikeLike
Reblogged this on MED.CHEM in BURMA.
LikeLike
Reblogged this on Med.Chem.in.Iceland.
LikeLike